{"product_id":"calcitonin-gene-related-peptide-cgrp-rat-full-length","title":"Calcitonin Gene Related Peptide (CGRP), Rat (Full-length)","description":"\u003cdiv style=\"max-width:1400px; margin:0 auto; padding:40px 20px; font-family:'Open Sans',sans-serif; font-weight:300; background:#fff; color:#333; font-size:0.95rem; box-sizing:border-box;\"\u003e\n  \u003cdiv style=\"display:flex; flex-direction:column; gap:20px;\"\u003e\n\u003ch2 style=\"margin:0; font-weight:600;\"\u003eCalcitonin Gene Related Peptide (CGRP), Rat (Full-length) – Catalog #B2026678\u003c\/h2\u003e\n\u003cp\u003eCalcitonin Gene-Related Peptide (CGRP) is a 37-amino-acid neuropeptide processed from the calcitonin precursor gene, present in both the central and peripheral nervous systems. Rat CGRP shares 87% sequence identity with human CGRP and is widely used in research to model and study human CGRP biology. The full-length form is active at CGRP receptors and mediates vasodilation, pain signaling, immune modulation, and stress responses.\u003c\/p\u003e\n\u003cdiv style=\"overflow-x:auto; max-width:100%; margin-bottom:20px;\"\u003e\n\u003ctable style=\"width:100%; max-width:640px; border-collapse:collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eCatalog number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eB2026678\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eLot number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eExpiration Date:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmount:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e0.5 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSequence length:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e37 amino acids (full-length)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSpecies:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eRat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSupplied as:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eApplications:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eFunctional studies of CGRP signaling, receptor binding assays, migraine and neuropeptide research, vasodilation and vascular biology studies, stress response and neuroinflammation research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e–20°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eCalcitonin gene-related peptide, CGRP, rat CGRP, neuropeptide, CGRP receptor agonist, calcitonin gene product, CGRPα, sensory neuropeptide, migraine peptide, vasodilator peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eGrade:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBiotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity \u0026gt;18 MΩ-cm) and are filtered through 0.22 um.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eScientific Overview\u003c\/h3\u003e\n\u003cp\u003eCGRP exists as two isoforms derived from alternative splicing of the calcitonin gene: α-CGRP (commonly called CGRP or CGRPα) and β-CGRP. The α-form is predominant in neuronal tissue and is the primary form used in research. CGRP is synthesized in primary sensory neurons of the dorsal root ganglia and trigeminal system, and in autonomic neurons throughout the body. Upon release, CGRP binds to a G-protein-coupled receptor complex (CGRP receptor) composed of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), activating intracellular cAMP signaling.\u003c\/p\u003e\n\u003cp\u003eThe full-length 37-amino-acid peptide is required for full receptor activation and is the bioactive form in vivo. This distinguishes it from the CGRP (8–37) fragment, which acts as a competitive antagonist at the CGRP receptor.\u003c\/p\u003e\n\u003cp\u003eKey applications include:\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eFunctional characterization of CGRP receptor signaling in neurons and smooth muscle\u003c\/li\u003e\n\u003cli\u003eMigraine research: studying CGRP's role in trigeminal nociception and vasodilation\u003c\/li\u003e\n\u003cli\u003eStructure–activity relationship (SAR) studies with CGRP receptor antagonists and monoclonal antibodies\u003c\/li\u003e\n\u003cli\u003eVascular biology and endothelial function studies\u003c\/li\u003e\n\u003cli\u003eNeuroinflammation and immune regulation research\u003c\/li\u003e\n\u003cli\u003eStress response and neuroendocrine studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eUsage \u0026amp; Handling Guidance\u003c\/h3\u003e\n\u003cp\u003eStore the lyophilized powder at –20°C in a desiccated environment. Upon receipt, briefly centrifuge the tube before opening to collect powder at the bottom. Reconstitute in sterile PBS, distilled water, or your chosen assay buffer to the desired concentration. CGRP is stable in acidic to neutral pH (pH 4–8) but degrades rapidly in alkaline conditions. Avoid repeated freeze–thaw cycles once reconstituted; prepare working aliquots and store at –20°C or –80°C for long-term use.\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Add sterile buffer to the vial to achieve desired concentration. Mix gently by pipetting; do not vortex vigorously.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Reconstituted peptide is stable for several weeks at 4°C and months at –20°C; avoid freeze–thaw cycles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBioactivity:\u003c\/strong\u003e Confirm bioactivity in your system; typical EC50 values range from 0.1–10 nM depending on receptor type and cell line.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEndotoxin:\u003c\/strong\u003e For sensitive cell-based assays, request COA\/TDS for endotoxin levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhat You Get\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e0.5 mg of full-length rat CGRP, lyophilized powder\u003c\/li\u003e\n\u003cli\u003eA highly pure, bioactive neuropeptide for functional and binding studies\u003c\/li\u003e\n\u003cli\u003eSufficient material for multiple dose–response experiments or receptor characterization assays\u003c\/li\u003e\n\u003cli\u003eFor research use only (RUO)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhy Researchers Choose It\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eHigh homology to human CGRP for translational migraine and pain research\u003c\/li\u003e\n\u003cli\u003eFull-length bioactive form, distinct from antagonistic fragments\u003c\/li\u003e\n\u003cli\u003eLyophilized format for long-term stability and ease of use\u003c\/li\u003e\n\u003cli\u003eWell-characterized in the literature for CGRP receptor signaling studies\u003c\/li\u003e\n\u003cli\u003eSuitable for both in vitro functional assays and structure–activity studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eFrequently Asked Questions (FAQ)\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat is the difference between this full-length CGRP and CGRP (8–37)?\u003c\/strong\u003e\u003cbr\u003eFull-length CGRP (1–37) is the active agonist at CGRP receptors and mimics the native peptide. CGRP (8–37) is a truncated fragment that acts as a competitive antagonist and blocks receptor activation; use the antagonist if you wish to inhibit CGRP signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow do I reconstitute the lyophilized powder?\u003c\/strong\u003e\u003cbr\u003eAdd sterile PBS or your assay buffer to the vial to reach the desired concentration. Mix gently and allow 5–10 minutes for complete dissolution. Brief centrifugation before opening can help recover powder stuck to the vial wall.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat is the molecular weight of rat CGRP?\u003c\/strong\u003e\u003cbr\u003eApproximately 3.8 kDa. Request the COA\/TDS for exact mass and lot-specific biochemical data.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I use this in vivo?\u003c\/strong\u003e\u003cbr\u003eThis product is for in vitro research use only. It has not been tested for pharmacokinetics, bioavailability, or safety in animal models or humans.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat assays work well with CGRP?\u003c\/strong\u003e\u003cbr\u003eRadioreceptor assays, ELISA-based detection, cAMP accumulation assays, calcium flux assays, whole-cell patch-clamp electrophysiology, and binding studies with CGRP receptor antagonists or antibodies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIs endotoxin testing available?\u003c\/strong\u003e\u003cbr\u003eRequest available lot documentation (COA\/TDS) which may include endotoxin and sterility data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin-top:20px; font-weight:bold; color:#c8102e;\"\u003eThis product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use in humans or animals.\u003c\/div\u003e\n\u003chr\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003cul style=\"padding-left:0; margin:0; list-style:none;\"\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eRussell FA, Salmon AM, Franzen L, Schemann M, Grundy D, Spina D, King CM, Grant AD. Calcitonin gene-related peptide: physiology and pathophysiology. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2014;94(4):1099-142.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00034.2013\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eGoodman EC, Iversen LL. Calcitonin gene-related peptide: novel neuropeptide. \u003cem\u003eLife Sci.\u003c\/em\u003e 1986;38(24):2169-78.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/0024-3205(86)90568-0\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eBrain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2004;84(3):903-34.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00037.2003\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eEdvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies. \u003cem\u003eNat Rev Neurol.\u003c\/em\u003e 2018;14(6):338-350.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1038\/s41582-018-0003-1\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eGoadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2017;97(2):553-622.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00034.2015\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Molecular Depot","offers":[{"title":"Default Title","offer_id":52809017491754,"sku":"BTS-B2026678","price":585.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/B2026678.png?v=1790859416","url":"https:\/\/bluetigerscientific.com\/products\/calcitonin-gene-related-peptide-cgrp-rat-full-length","provider":"Blue Tiger Scientific","version":"1.0","type":"link"}